Current treatment options for acanthosis nigricans

Nupur U Patel,1 Catherine Roach,1 Hossein Alinia,1 William W Huang,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, 2Department of Pathology, Wake Forest University School of Medicine, Winston-S...

Full description

Bibliographic Details
Main Authors: Patel NU, Roach C, Alinia H, Huang WW, Feldman SR
Format: Article
Language:English
Published: Dove Medical Press 2018-08-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
Online Access:https://www.dovepress.com/current-treatment-options-for-acanthosis-nigricans-peer-reviewed-article-CCID
Description
Summary:Nupur U Patel,1 Catherine Roach,1 Hossein Alinia,1 William W Huang,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, 2Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, 3Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA Abstract: Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. While the goal of therapy is to treat the primary cause, cosmetic resolution of AN lesions can be important for patients and their quality of life. Treatment options for AN have not been extensively studied; however, smaller powered clinical trials and case reports exist in the literature. Our review aims to explore and evaluate the current treatment options that exist for AN. Keywords: acanthosis nigricans, diabetes, obesity, hyperinsulinemia, dermatologic condition, dermatology, malignant acanthosis, pseudoacanthosis, metformin, isotretinoin, tretinoin, topical therapy
ISSN:1178-7015